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1. Introduction 
1.1 Regulation of HIF function 
Hypoxia-inducible factor (HIF) is a transcription factor that is a master regulator of cellular 
responses to hypoxia and regulates many genes that are required for adaptation to hypoxia. 
1HIF is composed of two subunits, HIF┙ and HIF┚. HIF┙ is composed of three family 
members, HIF-1┙, HIF-2┙ and HIF-3┙. 2Among these family members, HIF-1┙ and HIF-2┙ 
play crucial roles in hypoxic responses. HIF activity is regulated via two mechanisms in 
response to hypoxia. First, HIF┙ expression is dependent on oxygen levels. 1 Under 
normoxic conditions, HIF┙ is hydroxylated at specific proline residues via prolyl-
hydroxylase domain proteins (PHDs). The enzymatic activities of PHDs are dependent on 
oxygen levels. Hydroxylation of the proline residues of HIFs increases the interaction of 
HIF┙ with the von Hippel-Lindau (VHL) proteins, which recruit an E3 ubiquitin-protein 
ligase. In turn, HIF┙ is ubiquitinated and subsequently degraded by the proteasome. In 
hypoxic conditions, PHD activity is suppressed and HIF┙ degradation is reduced. In 
addition to protein levels, oxygen levels control the transcriptional activities of HIFs. 2The 
factors that inhibit HIF (FIHs) play central roles in the process. At normoxic conditions, FIHs 
catalyze hydroxylation of asparagine residues of HIF┙, which represses the interaction of 
HIF with the transcriptional coactivator CBP/P300. Using these mechanisms, HIF is 
activated during hypoxia under normal physiological conditions.  
2. Abnormal activation of HIFs in multiple myeloma 
Under physiological conditions, HIFs are active during hypoxia. However, HIFs can be 
activated in many types of cancer cells, even under normoxic conditions, by oncogene 
products, impaired activities of tumor suppressor genes,3 or the accumulation of metabolic 
glucose intermediates. 4 HIFs are known to be activated in multiple myeloma cells. The 
hypoxic microenvironment of multiple myeloma bone marrow and oxygen-independent 
mechanisms contribute to abnormal activation of HIFs in myeloma cells. Asosingh and 
colleagues reported HIF-1┙ expression in 5T2 MM cells in the mouse myeloma model. 
5These researchers showed that the hypoxic microenvironment of the bone marrow 
contributed to HIF-1 activation, especially in the initial stages of the disease. 5 Hypoxia-
induced HIF-1┙ expression in myeloma cells in multiple myeloma bone marrow was 
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reported by Hu et al, who used the murine 5T3MM myeloma model to demonstrate that the 
majority of myeloma cells localize in an extensively hypoxic region and show strong 
expression of HIF-1┙. 6The correlation between bone marrow hypoxia and HIF-1 activation in 
multiple myeloma cells was detected in human clinical samples. 7 Colla and colleagues 
analyzed the expression of HIF-1┙ in bone marrow biopsies and demonstrated HIF-1┙ 
immunostaining in the nuclei of myeloma cells in all multiple myeloma patients. 7 
Additionally, Colla and colleagues analyzed oxygen levels of bone marrow samples from 
multiple myeloma patients and found that the bone marrow of the myeloma patients was 
hypoxic. The researchers speculated that this hypoxia may cause the accumulation of HIF-1┙. 
However, the oxygen levels in the bone marrow of healthy volunteers were equivalent to 
those of myeloma patients. Therefore, it is not clear whether a reduced oxygen level in the 
bone marrow is the only inducer of HIF-1┙ expression. Colla and colleagues detected HIF-1┙ 
protein in isolated CD138-positive myeloma cells in approximately 28% of myeloma patients 
in normoxic conditions. 7 These observations suggest that the hypoxia-independent 
mechanisms regulate HIF-1┙ in multiple myeloma cells. Our group detected constitutive 
expression of HIF-1┙ in several multiple myeloma cell lines and in CD138-positive primary 
myeloma cells even in normoxic conditions. 8 We found that growth factors for myeloma cells, 
including insulin-like growth factor-1 (IGF-1) and IL-6, enhanced the expression of HIF-1┙ in 
myeloma cells through activation of AKT. LY294002, which is an inhibitor of PI3-kinase and 
AKT, inhibited IGF-1-induced HIF-1┙ elevation. 8 The oncogene product c-Myc is also 
involved in aberrant activation of HIF-1 under normoxia. 9 10Downregulation of c-Myc by 
chemical inhibitors or siRNA diminished HIF-1┙ expression levels in myeloma cells. 9 
Increased DNA methylation was detected in the promoter region of VHL11 and PHD12 genes 
in myeloma cells and may contribute to abnormal HIF activation. In addition to protein levels, 
transcriptional activity of HIFs is modulated in multiple myeloma cells. The inhibitor of 
growth family member 4 (ING4) is a tumor suppressor gene that is involved in the process. 
Colla et al. found that myeloma cells showed reduced ING4 expression, which inversely 
correlated with the expression of pro-angiogenic factors such as IL-8 and osteopontin. 13 Colla 
et al. concluded that ING4 suppressed HIF-1 function via PHD interactions.13 
Abnormal activation of HIF-2 is found in multiple myeloma cells. Martin et al. examined the 
expression of HIF-1┙ and HIF-2┙ with bone marrow trephine specimens from patients with 
multiple myeloma. 14 They detected weak HIF-1┙ expression in numerous types of bone 
marrow cells, whereas HIF-2┙ expression was strong and restricted to CD138-positive cells. 14 
Abnormal activation of HIF-2 was reported by another group. 15 In their study, the expression 
of HIF-1┙ and HIF-2 was assessed in the bone marrow of 106 multiple myeloma patients. 
Among the patients, HIF-1┙ and HIF-2 were expressed in 33% and 13.2%, respectively. 15The 
aforementioned findings indicate that HIF-1┙ and HIF-2 are activated in multiple myeloma 
cells using multiple mechanisms, including the hypoxic environment of the myeloma bone 
marrow, growth factors for myeloma cells and oncogene products (Fig.1).  
3. Role of abnormal HIF activation in the pathophysiology of MM 
HIF┙ forms a complex with the beta-subunit of HIF and binds conserved DNA sequences 
that are known as hypoxia-response elements (5’-RCGTG-3’) to regulate mRNA expression 
of target genes. 1HIFs regulate many genes that are required for adaptation to hypoxic 
conditions. Among the first group of genes regulated by HIF are pro-angiogenetic factors 
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Fig. 1. Abnormal activation of HIFs in multiple myeloma cells 
The bone marrow of multiple myeloma patients is hypoxic, which induces HIF activation in 
multiple myeloma cells. Growth factors activate HIFs via increased protein synthesis in 
myeloma cells. Overexpression of c-Myc and decreased ING4 enhance HIF activity. DNA 
methylation of the promoter regions of VHL and PDHs, which are required for HIF  
degradation, may enhance HIF levels. 
including vascular endothelial growth factor (VEGF), IL-8 and osteopontin. 13 HIFs regulate 
several chemokines and their receptors SDF-116 (also known as CXCL12) and CXCR4. 17 
Several anti-apoptotic proteins are also HIF targets. HIF-1 regulates the Bcl-2 family of anti-
apoptotic proteins: Bcl-xL18 and Mcl-1. 19 Furthermore, HIF-1 controls the expression of 
survivin, which is a member of the inhibitor for apoptosis family of proteins (IAPs). 20 Under 
hypoxic conditions, glucose metabolism is shifted from oxidative phosphorylation, which 
requires oxygen, to glycolysis. HIFs contribute to this metabolic shift21 via up-regulation of 
glycolytic enzymes including glucose transporters, hexokinase and pyruvate dehydrogenase 
kinase (PDK). 22-24In addition, HIFs suppress mitochondrial function to reduce oxidative 
phosphorylation. 21 
Aberrant HIF activation in multiple myeloma cells enhances the expression of these genes 
and contributes to the pathophysiology of multiple myeloma. HIFs enhance VEGF 
production in myeloma cells. 9In addition, HIF-1 may contribute to increased angiogenesis 
via up-regulation of IL-8 and osteopontin. 13 Osteopontin stimulates the survival and 
migration of endothelial cells to enhance angiogenesis. 25 HIF-2 activation induces CXCL12 
expression, which contributes to aberrant angiogenesis. 14 The promoter of CXCL12 has 
several hypoxia responsive elements (HREs). Treatment of myeloma cell lines with hypoxia 
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increases the binding of HIF-2 to HRE on the CXCL12 promoter and enhances 
transcriptional activity. Ectopic expression of HIF-2 in myeloma cells increases production 
of CXCL2. The role of CXCL12 in angiogenesis was revealed by a study using a mouse 
xenograft model. In this model, the addition of an agonist for CXCR4, which is a receptor for 
CXCL12, inhibited angiogenesis. 14 In addition to pathological angiogenesis, HIFs induce 
survival molecules in multiple myeloma cells. We found that activation of HIF-1 by IGF-1 
enhanced the expression of the anti-apoptotic protein survivin. 8 Recently, target genes of 
HIFs in multiple myeloma cells were analyzed using high-throughput methods. 7 Colla et al. 
compared the transcriptional profile of CD138-positive myeloma cells under normoxia and 
treated with the hypoxic mimetic drug CoCl2. They detected 714 genes that were 
significantly modulated by hypoxia including heme oxygenase-1, heat shock protein 90 
(Hsp90), VEGF and IL-8. 7 In summary, HIFs contribute to the pathogenesis of multiple 
myeloma by inducing the expression of their target genes to enhance angiogenesis in the 
bone marrow and suppressing apoptosis in myeloma cells (Fig. 2). 
 
Fig. 2. Pathological role of HIFs in multiple myeloma  
HIF activation induces the production of several pro-angiogenetic factors and enhances 
angiogenesis in the bone marrow. HIFs suppress apoptosis in myeloma cells by inducing 
anti-apoptotic factors. 
4. HIFs as therapeutic targets for multiple myeloma 
As described above, evidence has accumulated that implicates the important role of HIFs in 
the pathophysiology of multiple myeloma. These findings suggest the possibility for new 
therapeutic approaches that target hypoxic bone marrow microenvironments and HIFs. Our 
group showed that inhibition of HIF-1 function via the chemical inhibitor echinomycin26, 
which disrupts HIF binding to DNA, or siRNA against HIF-1┙ disrupted the anti-apoptotic 
effects of IGF-1. 8 Importantly, echinomycin enhanced melphalan-induced apoptosis in 
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primary CD138-positive myeloma cells. 8 Zhang et al. found that adaphostin, which is a 
tyrphostin kinase inhibitor, 27 28blocked expression of c-Myc and HIF-1┙ in several multiple 
myeloma cells. 9 They reported that adaphostin down-regulated c-Myc and HIF-1┙ in the 
xenograft mouse myeloma model. In this model, the compound suppressed VEGF secretion, 
tumor angiogenesis and tumor progression and increased the survival of the animals. 9 
Known anti-myeloma drugs inhibit function of HIFs. Bortezomib suppresses transcriptional 
activity of HIF-1. 29Lenalidomide inhibits the synthesis of HIF-1┙ in endothelial cells and 
suppresses the expression of HIF-1┙ in multiple myeloma cells. 30Recent studies also 
revealed that HIFs were molecular targets of a new generation of agents against multiple 
myeloma. A molecular chaperone, heat shock protein 90 (Hsp90), stabilizes a series of 
proteins that are required for cell cycle progression and survival. 31 In multiple myeloma 
cells, Hsp90 is known to enhance survival, and several inhibitors for HSp90 show anti-
myeloma effects. 31 Interestingly, HIF-1┙ is a target protein for Hsp90. 32 Treatment of 
myeloma cells with Hsp90 inhibitor blocked expression of HIF-1┙ expression. 32Together 
with these observations, there is evidence that Hsp90 inhibitor may exert anti-myeloma 
effects through the suppression of HIFs. Histone deacetylase (HDAC) inhibitors are 
attractive new-generation agents against multiple myeloma. 33 HDAC inhibitors suppress 
the growth and survival of myeloma cells in vitro. 34 Furthermore, several HDAC inhibitors 
are currently being used in clinical trials. 35Although the main target of HDAC inhibitors is 
histone deacetylase, the inhibitors modify the function of numerous proteins including 
HIFs. The HDAC inhibitor induces the degradation of HIF-1┙ independent of VHL function. 
36 37Taken together, HIFs may be a molecular target of HDAC inhibitors in multiple 
myeloma. Finally, TH-302, which is a hypoxia-activated prodrug, 38 shows significant anti-
myeloma effects in the murine myeloma model. 6 These results suggest that the hypoxic 
environment of multiple myeloma bone marrow might be an attractive therapeutic target. 
5. Conclusions 
The microenvironment of bone marrow is hypoxic in multiple myeloma and supports the 
survival and growth of myeloma cells, especially during the initial stage of the disease. 
Hypoxia enhances HIF activity and induces the production of pro-angiogenetic factors. 
Subsequently, angiogenesis in the bone marrow is enhanced and supports further growth of 
myeloma cells. 39 Growth factors for myeloma cells and intrinsic cellular changes (i.e., 
increased c-Myc expression and reduced ING4 levels) modify HIF activity and may 
contribute to increased angiogenesis. Furthermore, HIFs are survival factors for myeloma 
cells that induce the production of anti-apoptotic proteins and may be involved in the 
acquisition of drug-resistance. Treatments targeting both HIFs and hypoxic 
microenvironments represent novel strategies to improve treatment outcomes for multiple 
myeloma. 
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